CAR-T specialist Caribou culls pipeline and seeks exit deal
Caribou Biosciences, a biotech developing off-the-shelf cell therapies for blood cancers, said it will discontinue its pipeline and lay off…
07 Oct 2026
KymaThera pulls in $80m to bring breast cancer drug to clinic
San Diego-based biotech KymaThera has banked $80m in a Series B funding round to bring a breast cancer drug to clinic that it claims may overcome the challenges linked to…
07 Oct 2026
Rocket receives $150m credit facility to advance cardiovascular portfolio
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing development of its cardiovascular portfolio. The financing arrangement extends the…
07 Oct 2026
Gilead Sciences signs five-year DevOps agreement with Cognizant
Gilead Sciences has signed a five-year agreement extension with Cognizant to advance its DevOps environment and support the deployment of agentic AI tools across designated technology initiatives. The renewed arrangement…
06 Oct 2026
Shionogi bolsters rare disease portfolio with $2bn IntraBio buyout
Japanese pharma company, Shionogi, is set to acquire IntraBio in a multibillion-dollar deal, adding neurological and movement disorder drug, Aqneursa (levacetylleucine), to its portfolio and marking its fortification in the…
06 Oct 2026
Lilly deepens ties with Gate Bioscience in $870m deal expansion
Eli Lilly has expanded its partnership and licensing agreement with California-based biotech, Gate Bioscience, to develop molecular gate therapies targeting difficult-to-drug proteins. As per the terms of this extended, multi-year…
06 Oct 2026
Alector shares up after sealing $1.27bn Roche Parkinson’s disease license deal
Roche is paying up to $1.27bn to gain the global rights to Alector’s Parkinson’s disease candidate, giving the drugmaker access to a drug that aims to overcome delivery limitations that…